April 2026
1. SHARMA S, Thivierge B, Liu Q
   A bivalent subunit vaccine elicits robust immune responses and neutralizing antibodies against genogroup 1b and 2b porcine epidemic diarrhea viruses.
   Virology. 2026;617:110824.
   

   >> Share

   
   
2. WUBSHET AK, Ding Y, Zhou L, Wang Y, et al
   Development of baculovirus-derived bovine parvovirus VP2based chimeric virus-like particles co-displaying SAT2 FMDV VP1 B- and T-cell epitopes and evaluation of humoral and cellular immune responses in BALB/c mice.
   Virology. 2026;617:110812.
   

   >> Share

   
   
3. LIU H, Ma Y, Hou F, Teng Z, et al
   Combination immunization with mRNAs encoding PRRSV antigens enhances immune responses and confers protective immunity against highly pathogenic PRRSV in piglets.
   Virology. 2026;617:110810.
   

   >> Share

   
   February 2026
4. LI Z, Zhao M, Zhang G, Cheng J, et al
   Spike 1 trimer subunit vaccines against porcine epidemic diarrhea virus effectively induce protective immunity challenge in piglets.
   Virology. 2026;617:110823.
   

   >> Share

   
   
5. LI J, Yang Q, Yang Z, Huyan Y, et al
   Structural and immunogenic characteristics of goose parvovirus virus-like particles.
   Virology. 2026;614:110727.
   

   >> Share

   
   January 2026
6. VADIBELER S, Mandal H, Ooi S, Atiya N, et al
   Barriers to dengue vaccine coverage in low- and middle-income countries (LMICs).
   Virology. 2026;617:110821.
   

   >> Share

   
   
7. THOMAS MH, Carlock MA, Ross TM
   Adjuvants enhance protective antibodies against seasonal influenza viruses following a single vaccination of Fluzone.
   Virology. 2026;616:110787.
   

   >> Share

   
   December 2025
8. NGUYEN CT, Nakayama M, Yasui F, Ishigaki H, et al
   Vaccinia virus-based SARS-CoV-2 vaccine prevents lung immunopathology without antibody-dependent enhancement in female rhesus macaques.
   Virology. 2025;616:110778.
   

   >> Share

   
   November 2025
9. LONG J, Liu K, Chen Y, Wang X, et al
   Attenuation of a contemporary Chinese PRRSV-1 strain via serial cell passage and evaluation of its protective efficacy as a modified live virus vaccine candidate.
   Virology. 2025;615:110746.
   

   >> Share

   
   
10. BRICE DC, Andreev K, Miller L, Patton C, et al
    Immunogenicity and efficacy of commercial poultry avian influenza vaccines against HPAI A(H5N1) clade 2.3.4.4b viruses in Mexico.
    Virology. 2025;615:110765.
    

    >> Share

    
    September 2025
11. ELHAZAZ FERNANDEZ A, Abidi S, Mahl K, Scheffler D, et al
    A chiropteran factor of innate immunity can be recruited for rapid rescue and amplification of recombinant modified vaccinia Ankara (MVA).
    Virology. 2025;612:110698.
    

    >> Share

    
    
12. KIM KH, Hwang HS, Lee Y, Jung YJ, et al
    Interferon-gamma receptor signaling is critical for balanced immune activation and protection against influenza after vaccination.
    Virology. 2025;612:110674.
    

    >> Share

    
    August 2025
13. QIAO Y, Tang M, Du M, Zhao C, et al
    H5N1 influenza virus-like particles based on BEVS induce robust functional antibodies and immune responses.
    Virology. 2025;612:110672.
    

    >> Share

    
    
14. BABA S, Koyama T, Komatsu D, Uchino T, et al
    Development of an effective DNA vaccine against ayu atypical cellular gill disease using draft genome information of the causative agent, Plecoglossus altivelis poxvirus.
    Virology. 2025;612:110671.
    

    >> Share

    
    
15. ZENG F, Liu Q, Wang X, Zhong P, et al
    Immunoinformatics design and experimental expression of a multi-epitope vaccine simultaneously targeting AAV2 and HAdV-F41 against acute hepatitis of unknown etiology.
    Virology. 2025;611:110653.
    

    >> Share

    
    
16. ZHANG S, Liu G, Guo A, Chen Y, et al
    Maternal antibody transfer efficiency: The impact of M. bovis-BoHV-1 combined vaccine.
    Virology. 2025;611:110656.
    

    >> Share

    
    June 2025
17. YIN W, Chang C, Zhu Y, Ma F, et al
    Construction of vitamin E-based oil-in-water nano-emulsion adjuvant enhances immunogenicity of inactivated pseudorabies virus vaccine.
    Virology. 2025;610:110616.
    

    >> Share

    
    
18. PASQUALE S, Moscara L, Palmieri C, Martinelli A, et al
    Safety of SARS-CoV-2 XBB.1.5 and seasonal influenza vaccines co-administration: data from a perspective observational active surveillance study. Puglia (Italy), season 2023/2024.
    Virology. 2025;610:110613.
    

    >> Share

    
    
19. FENG S, Huang M, Quan Y, Sun L, et al
    The spike 486 site is a key immune evasion point and a determinant of the immunogenicity of the RBD-dimer mRNA vaccine against SARS-CoV-2 variants.
    Virology. 2025;610:110612.
    

    >> Share

    
    
20. YANG H, Song W, Li Z, Zhu Z, et al
    Genomic characteristics and pathogenicity of three newly isolated NADC34-like PRRSV strains in China and evaluation of one strain for inactivated vaccine candidate.
    Virology. 2025;610:110605.
    

    >> Share

    
    
21. TABYNOV K, Kuanyshbek A, Zharmambet K, Yelchibayeva L, et al
    Evaluation of commercial vaccines for efficacy and transmission control against the emergent H5N8 (clade 2.3.4.4b) avian influenza virus in Kazakhstan.
    Virology. 2025;610:110601.
    

    >> Share

    
    
22. BEAUDOIN-BUSSIERES G, Tauzin A, Dionne K, El Ferri O, et al
    Multiple exposures to SARS-CoV-2 Spike enhance cross-reactive antibody-dependent cellular cytotoxicity against SARS-CoV-1.
    Virology. 2025;607:110512.
    

    >> Share

    
    May 2025
23. SONI S, Kennedy MA, Wang D, Li F, et al
    The role and implication of rotavirus VP8 * in viral infection and vaccine development.
    Virology. 2025;609:110563.
    

    >> Share

    
    
24. CHOI KY, McGregor A
    The guinea pig as a relevant preclinical model in the rat race for a vaccine against congenital cytomegalovirus infection.
    Virology. 2025;610:110560.
    

    >> Share

    
    
25. ISHIGAKI H, Itoh Y
    Translational research on pandemic virus infection using nonhuman primate models.
    Virology. 2025;606:110511.
    

    >> Share

    
    April 2025
26. XU J, Zhang B, Wang B, Ye Z, et al
    The PB subunit vaccine evokes immune response against fox encephalitis.
    Virology. 2025;609:110561.
    

    >> Share

    
    
27. JIANG FY, Xia JY, Jia YJ, Zhu B, et al
    Multi-epitope microsphere vaccine modified immunological efficacy against LMBV in largemouth bass (Micropterus salmoides).
    Virology. 2025;608:110553.
    

    >> Share

    
    
28. SUZUKI Y
    Application of reverse genetics system to Chikungunya virus study.
    Virology. 2025;605:110465.
    

    >> Share

    
    March 2025
29. RAHA JR, Kim KH, Tien Le CT, Bhatnagar N, et al
    A strategy of enhancing the protective efficacy of seasonal influenza vaccines by providing additional immunity to neuraminidase and M2e.
    Virology. 2025;606:110510.
    

    >> Share

    
    
30. BANGA NDZOUBOUKOU JL, Kamara AA, Ullah N, Lei Q, et al
    A meta-analysis on the immunogenicity of prototype, monovalent-adapted and bivalent vaccines against SARS-CoV-2 wildtype, Omicron BA.1 and Omicron BA.4/5 in healthy adults.
    Virology. 2025;606:110509.
    

    >> Share

    
    
31. ZENG L, Bai J, Huang J, Huang S, et al
    Construction and preliminary immunological evaluation of EV-G replicon expressing PEDV-COE-N region.
    Virology. 2025;604:110436.
    

    >> Share

    
    January 2025
32. KORNUTA CA, Bidart JE, Soria I, Quattrocchi V, et al
    Galectin-8 and GEL01 as potential adjuvants to enhance the immune response induced by a DNA vaccine against bovine alphaherpesvirus Type-1.
    Virology. 2025;604:110402.
    

    >> Share

    
    
33. FRAGOSO-SAAVEDRA M, Liu Q
    Towards developing multistrain PEDV vaccines: Integrating basic concepts and SARS-CoV-2 pan-sarbecovirus strategies.
    Virology. 2025;604:110412.
    

    >> Share

    
    
34. WANG N, Yuan C, Wang Z, Yu C, et al
    An effective antiviral strategy based on silence of susceptibility genes through cucumber mosaic virus (CMV) attenuated vaccine vector.
    Virology. 2025;603:110396.
    

    >> Share

    
    
35. ZHAO Y, Li W, Xu L, Tao Z, et al
    Antibody responses in omicron BF.7-infected patients vaccinated with inactivated SARS-CoV-2.
    Virology. 2025;603:110404.
    

    >> Share

    
    
36. SAHA A, Choudhary S, Walia P, Kumar P, et al
    Transformative approaches in SARS-CoV-2 management: Vaccines, therapeutics and future direction.
    Virology. 2025;604:110394.
    

    >> Share

    
    
37. SULTANA R, Stahelin RV
    Strengths and limitations of SARS-CoV-2 virus-like particle systems.
    Virology. 2025;601:110285.
    

    >> Share

    
    
38. YANG M, Jiao Y, Yan Y, Fu Z, et al
    Recombinant feline herpesvirus-1 (FHV-1) expressing granulocyte colony-stimulating factor (G-CSF) exhibits enhanced protective efficacy in felines.
    Virology. 2025;601:110282.
    

    >> Share

    
    
39. HU W, Tang D, Zeng Z, Wang B, et al
    Research progress on the molecular mechanism of immune escape of porcine reproductive and respiratory syndrome virus.
    Virology. 2025;602:110298.
    

    >> Share

    
    December 2024
40. CALDERON-PEREZ B, Nunez-Munoz LA, Trejo-Ayala LL, Rosales-Garcia VH, et al
    Immunogenicity of a multivalent protein subunit vaccine based on non-glycosylated RBD antigens of SARS-cov-2 and its variants.
    Virology. 2024;603:110380.
    

    >> Share

    
    
41. PENG Y, Luo Y, Pan L, Hou Y, et al
    Immunogenicity analysis based on VP1 and VP2 proteins of bovine enterovirus.
    Virology. 2024;600:110260.
    

    >> Share

    
    November 2024
42. CARCHMAN E, Sanger CB
    Anal cancer prevention: A field in need of scientific Advancement.
    Virology. 2024;602:110323.
    

    >> Share

    
    
43. JIN H, Zhao YR, Huang F, Hong Z, et al
    Vaccinia virus-mediated oncolytic immunotherapy: Emerging strategies for gastrointestinal cancer treatment at dawn.
    Virology. 2024;602:110303.
    

    >> Share

    
    
44. ALI AA, Tabll AA
    Unlocking potential: Virus-like particles as a promising strategy for effective HCV vaccine development.
    Virology. 2024;602:110307.
    

    >> Share

    
    
45. ZHANG J, Pan W, Wang Y, Zhang C, et al
    Corrigendum to "Enhancing vaccine efficacy: Evaluating the superiority of cationic liposome-squalene adjuvant against PCV2 infection" [Virology (2024) 110251].
    Virology. 2024 Nov 7:110271. doi: 10.1016/j.virol.2024.110271.
    

    >> Share

    
    October 2024
46. ZHANG J, Pan W, Wang Y, Zhang C, et al
    Corrigendum to "Enhancing vaccine efficacy: Evaluating the superiority of cationic liposome-embedded squalene adjuvant against PCV2 infection" [Virol. 600 (2024) 110251].
    Virology. 2024 Oct 21:110263. doi: 10.1016/j.virol.2024.110263.
    

    >> Share

    
    September 2024
47. RAHARINANTOANINA J, Joffret ML, Bessaud M, Rakoto DAD, et al
    Wide circulation of type 1 vaccine-derived poliovirus strains in clinical specimens from suspected cases of poliomyelitis, their contacts and in wastewater in Madagascar since late 2020.
    Virology. 2024;600:110253.
    

    >> Share

    
    
48. ZHANG J, Pan W, Wang Y, Zhang C, et al
    Enhancing vaccine efficacy: Evaluating the superiority of cationic liposome-embedded squalene adjuvant against PCV2 infection.
    Virology. 2024;600:110251.
    

    >> Share

    
    
49. JANG SO, Lee JH, Chung YJ, Oh HS, et al
    Chimeric adenovirus-based herpes zoster vaccine with the tPA signal peptide elicits a robust T-cell immune response.
    Virology. 2024;600:110243.
    

    >> Share

    
    
50. HERMANN S, Stevens MJA, Sigrist B, Bilic I, et al
    Unveiling the genetic landscape of infectious laryngotracheitis virus in Switzerland: Evidence for vaccine-like and wild-type strains.
    Virology. 2024;600:110217.
    

    >> Share

    
    
51. HUANG WC, Baker WS, Lovell JF, Schein CH, et al
    Displaying alphavirus physicochemical consensus antigens on immunogenic liposomes enhances antibody elicitation in mice.
    Virology. 2024;597:110152.
    

    >> Share

    
    
52. LEI Y, Xu N, Niu C, Chen L, et al
    Specific immunological characteristics and risk factor of XBB variants re-infection in nasopharyngeal carcinoma patients after BA.5 infection.
    Virology. 2024;597:110142.
    

    >> Share

    
    
53. LI S, Tang X, Zhou J, Bian X, et al
    The synergy of recombinant NSP4 and VP4 from porcine rotavirus elicited a strong mucosal response.
    Virology. 2024;597:110130.
    

    >> Share

    
    July 2024
54. MANDVIWALA AS, Huckriede ALW, Arankalle VA, Patil HP, et al
    Mucosal delivery of a prefusogenic-F, glycoprotein, and matrix proteins-based virus-like particle respiratory syncytial virus vaccine induces protective immunity as evidenced by challenge studies in mice.
    Virology. 2024;598:110194.
    

    >> Share

    
    
55. HOUTA MH, Hassan KE, Kilany WH, Shany SAS, et al
    Evaluation of different heterologous-homologous vaccine regimens against challenge with GI-23 lineage infectious bronchitis virus.
    Virology. 2024;598:110193.
    

    >> Share

    
    
56. GILLOT C, Tre-Hardy M, Cupaiolo R, Blairon L, et al
    Assessment of the neutralizing antibody response in Omicron breakthrough cases in healthcare workers who received the homologous booster of Moderna mRNA-1273.
    Virology. 2024;595:110082.
    

    >> Share

    
    June 2024
57. ZHU H, Li X, Li X, Chen H, et al
    Protection against the H1N1 influenza virus using self-assembled nanoparticles formed by lumazine synthase and bearing the M2e peptide.
    Virology. 2024;597:110162.
    

    >> Share

    
    
58. ZHANG B, Li S, Zhou J, Wang W, et al
    A novel virus-like particles vaccine induces broad immune protective against deltacoronavirus in piglets.
    Virology. 2024;597:110150.
    

    >> Share

    
    
59. KIM J, Villar Z, Jobe O, Rerks-Ngarm S, et al
    Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1.
    Virology. 2024;597:110158.
    

    >> Share

    
    
60. ABDEL-MONEIM AS, Murovska M, Soderlund-Venermo M, Vakharia VN, et al
    WSV2023 - The second meeting of the world society for virology: One health - One world - One virology.
    Virology. 2024;594:110049.
    

    >> Share

    
    
61. HE X, Jiang N, Li Y
    Saccharomyces cerevisiae cells that display norovirus P induce both systemic and mucosal neutralizing antibodies.
    Virology. 2024;594:110034.
    

    >> Share

    
    
62. GE P, Ross TM
    COBRA HA and NA vaccination elicits long-live protective immune responses against pre-pandemic H2, H5, and H7 influenza virus subtypes.
    Virology. 2024;597:110119.
    

    >> Share

    
    May 2024
63. TIAN Y, Deng Z, Chuai Z, Li C, et al
    A combination influenza mRNA vaccine candidate provided broad protection against diverse influenza virus challenge.
    Virology. 2024;596:110125.
    

    >> Share

    
    
64. BROGAARD L, Heegaard PMH, Larsen LE, Skovgaard K, et al
    Pulmonary MicroRNA expression after heterologous challenge with swine influenza A virus (H1N2) in immunized and non-immunized pigs.
    Virology. 2024;596:110117.
    

    >> Share

    
    
65. YANG D, Wang X, Yang X, Qi S, et al
    Construction and immune effect evaluation of the S protein heptad repeat-based nanoparticle vaccine against porcine epidemic diarrhea virus.
    Virology. 2024;596:110113.
    

    >> Share

    
    
66. SHAO J, Liu W, Gao S, Chang H, et al
    A recombinant multi-epitope trivalent vaccine for foot-and-mouth disease virus serotype O in pigs.
    Virology. 2024;596:110103.
    

    >> Share

    
    April 2024
67. MA X, Wang Q, Xu X, Zhang W, et al
    miR-214-PTEN pathway is a potential mechanism for stress-induced immunosuppression affecting chicken immune response to avian influenza virus vaccine.
    Virology. 2024;595:110094.
    

    >> Share

    
    
68. KIM KH, Bhatnagar N, Subbiah J, Liu R, et al
    Cross-protection against influenza viruses by chimeric M2e-H3 stalk protein or multi-subtype neuraminidase plus M2e virus-like particle vaccine in ferrets.
    Virology. 2024;595:110097.
    

    >> Share

    
    March 2024
69. AMOSOVA IV, Timoshicheva TA, Kadyrova RA, Zabrodskaya YA, et al
    The investigation of the dynamics of changes in neutralizing antibody titers against type 5 adenovirus in the context of vaccination against a new coronavirus infection.
    Virology. 2024;594:110051.
    

    >> Share

    
    
70. ZHENG X, Yang R, Zhao Y, Zhang Y, et al
    Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity.
    Virology. 2024;594:110050.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share